Menstrual Cramps Treatment Market By Type, By Treatment, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Primary Dysmenorrhea
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Secondary Dysmenorrhea
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country

CHAPTER 5: MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Non-steroidal Anti-inflammatory Drugs
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Hormonal Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country

CHAPTER 6: MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country

CHAPTER 7: MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Treatment
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Treatment
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Treatment
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Treatment
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Treatment
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Treatment
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Treatment
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Treatment
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Treatment
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Treatment
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Treatment
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Treatment
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Treatment
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Treatment
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Treatment
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Treatment
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Treatment
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Treatment
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Treatment
7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bayer AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Johnson and Johnson
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Taj Pharmaceuticals Limited
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Torrent Pharmaceuticals Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Abbott Laboratories
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Dr. Reddy's Laboratories Ltd.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 GlaxoSmithKline plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sun Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Menstrual Cramps Treatment Market,' the menstrual cramps treatment market size was valued at $560.89 million in 2021, and is estimated to reach $841.6 million by 2031, growing at a CAGR of 4.1% from 2022 to 2031.

Dysmenorrhea is a medical term for menstrual cramps in which a woman feels severe cramps in her lower abdomen that can spread to her lower legs and back. It is a painful sensation that affects many people before and during a menstrual period. It has two types including primary dysmenorrhea and secondary dysmenorrhea.

Primary dysmenorrhea is pain that only occurs during menstruation and secondary dysmenorrhea is a period pain caused by a medical condition, such as endometriosis, uterine fibroids, or pelvic inflammatory disease. During menstruation, prostaglandins are chemicals that are secreted into the uterine lining. These prostaglandins cause painful uterine muscle contractions and reduce blood and oxygen flow to the uterus which causes menstrual cramps. Menstrual cramps are frequently relieved with over-the-counter pain relievers such as Ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) can help with pain relief.

Menstrual cramps treatment market trends that drive growth of the market include rise in prevalence of dysmenorrhea caused due to environmental factors and changes in lifestyles along with unhealthy eating habits. For instance, according to a Journal published by the American College of Obstetricians and Gynecologists (ACOG), in 2021, the prevalence rate of dysmenorrhea rage from 50% to 90%.

In addition, major players are investing in the development and commercialization of menstrual cramps treatment to decrease incidences of dysmenorrhea further fuel the growth during menstrual cramps treatment market analysis. On the other hand, side effects associated with drug treatment may hamper the market growth. For instance, naproxen drug used to reduce the menstrual cramps can cause bloating, drowsiness, nausea and vomiting.

Moreover, rise in R&D activities for menstrual cramps drugs further boost the growth menstrual cramps treatment market forecast. Moreover, rise in awareness among women regarding menstrual cramps treatment, is expected to propel the market growth. Furthermore, rise in prevalence of reproductive track anomalies which causes secondary dysmenorrhea is expected to propel the market growth during the forecast period. For instance, according to a journal published by American College of Obstetricians and Gynecologists (ACOG), in 2021, the estimated occurrence of reproductive track anomalies is 0.1-3.8% of young women.

On the basis of type, the market is bifurcated into primary dysmenorrhea and secondary dysmenorrhea. The primary dysmenorrhea segment exhibited highest menstrual cramps treatment market share in 2021, and is expected to remain dominant during the forecast period, owing to rise in prevalence of primary dysmenorrhea. In addition, rise in depression and anxiety, attempts to lose weight are the factors responsible to cause primary dysmenorrhea and further drive the segment growth.

On the basis of treatment, the market is segmented into non-steroidal anti-inflammatory drugs and hormonal therapy. The non-steroidal anti-inflammatory drugs exhibited highest growth in 2021, and is expected to remain dominant during the forecast period, owing to high adoption of non-steroidal anti-inflammatory drugs due to rise in prevalence of primary and secondary dysmenorrhea.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies dominated the menstrual cramps treatment industry in 2021, owing to it provide better financial and debt management to patients. Moreover, the online providers segment is projected to register a highest CAGR during the forecast period, owing to availability of a menstrual cramp drugs such as ibuprofen and naproxen sodium on e-commerce platforms is more than pharmacies/retail stores, which helps patients buy products at ease.

Region wise, North America held the highest menstrual cramps treatment market share in 2021, and is expected to maintain its lead during the forecast period, owing to increase in demand for menstrual cramps treatment due to rise in prevalence of dysmenorrhea. In addition, rise in awareness regrading menstrual cramps treatment in this region boost the market growth. However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, owing to increase in health awareness and rise in number of hospitals equipped with advanced medical facilities.

Key findings of the study

• By type, the primary dysmenorrhea segment was highest contributor to the menstrual cramps treatment industry in 2021.
• On the basis of treatment, the non-steroidal anti-inflammatory drugs segment was dominated the market in 2021.
• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2021. However, online providers segment is anticipated to grow at the highest CAGR of during the forecast period.
• Region wise, North America generated the largest revenue in the menstrual cramps treatment market size in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of during the forecast period.

Companies Mentioned

• Abbvie Inc.
• Bayer AG
• Johnson and Johnson
• Taj Pharmaceuticals Limited
• Torrent Pharmaceuticals Ltd.
• Abbott Laboratories
• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• GlaxoSmithKline PLC
• Sun Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.